|Articles|August 25, 2020
ERT and Science 37 Partner to Deliver Data During Virtual Trials
Advertisement
ERT and Science 37 have announced a partnership enabling ERT’s Cardiac Safety, Respiratory, and Imaging solutions to be incorporated into the Science 37 virtual, or decentralized clinical trial offering.
The ERT and Science 37 partnership enables sponsors to capture the same data in a virtual model as it would in a traditional model, while aiming to reduce patient burden, minimize patient risk, and enable study continuity.
“Given the challenges caused by COVID-19, trial sponsors need effective virtual trial solutions that enable patients to participate safely, without jeopardizing data quality,” said Jim Corrigan, CEO at ERT. “We’re pleased to partner with Science 37 and to expand the use of our Respiratory, Cardiac Safety and Imaging solutions to support virtual trials throughout the pandemic and beyond.”
During home and telemedicine visits, Science 37 will use ERT’s proven remote respiratory and cardiac safety data collection solutions. Additionally, Science 37 will leverage ERT’s Imaging services through a local-care network—helping to limit patient travel with medical imaging services closer to home.
For the full release, click here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
3
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
4
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
5